Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

Rhea-AI Summary

Werewolf Therapeutics (Nasdaq: HOWL) announced it will present two posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting in Houston, Texas, from November 6-10, 2024. The first poster, titled 'INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in Murine Syngeneic Tumor Models' (Abstract 955), will be presented on November 8. The second poster, 'The tumor-activated IL-12 prodrug WTX-330 expanded/activated tumor infiltrating lymphocytes and caused tumor regression in patients with refractory solid tumors: Interim data from an ongoing Ph1 study' (Abstract 672), will be presented on November 9.

Both presentations will take place at the George R. Brown Convention Center - Exhibit Halls A B. Werewolf Therapeutics is a biopharmaceutical company focused on developing conditionally activated therapeutics to stimulate the immune system for cancer treatment.

News Market Reaction

+1.00%

1 alert

+1.00% News Effect

On the day this news was published, HOWL gained 1.00%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.

Details for the poster presentations are as follows:

Title: INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in Murine Syngeneic Tumor Models
Abstract Number: 955
Session Date and Time: Friday, Nov. 8, 2024; 9 a.m.–8:30 p.m.
Location: George R. Brown Convention Center - Exhibit Halls A B

Title: The tumor-activated IL-12 prodrug WTX-330 expanded/activated tumor infiltrating lymphocytes and caused tumor regression in patients with refractory solid tumors: Interim data from an ongoing Ph1 study
Abstract Number: 672 
Session Date and Time: Saturday, Nov. 9, 2024; 9 a.m.–8:30 p.m.
Location: George R. Brown Convention Center - Exhibit Halls A B

About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf leverages its proprietary PREDATOR^® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. The Company’s INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Werewolf’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 as a single agent in multiple tumor types and Non-Hodgkin Lymphoma. To learn more visit www.werewolftx.com.

WEREWOLF^®, the WEREWOLF logo, PREDATOR^®, INDUKINE^™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.

Investor Contact:
John Norton
Precision AQ
212.362.1200
John.Norton@precisionaq.com

Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com

Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com

FAQ

What posters will Werewolf Therapeutics (HOWL) present at SITC 2024?

Werewolf Therapeutics will present two posters at SITC 2024: one on INDUKINE™ Molecules and their anti-tumor efficacy in murine models, and another on the tumor-activated IL-12 prodrug WTX-330 and its effects on patients with refractory solid tumors.

When and where will SITC's 39th Annual Meeting take place?

The Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting will take place from November 6-10, 2024, in Houston, Texas, at the George R. Brown Convention Center.

What is the focus of Werewolf Therapeutics' (HOWL) research?

Werewolf Therapeutics focuses on developing conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer.

What are the abstract numbers for Werewolf Therapeutics' (HOWL) SITC 2024 presentations?

The abstract numbers for Werewolf Therapeutics' presentations at SITC 2024 are 955 for the INDUKINE™ Molecules poster and 672 for the WTX-330 poster.